Article
Oncology
Suguru Uemura, Daiichiro Hasegawa, Kenji Kishimoto, Tomoko Fujikawa, Sayaka Nakamura, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Takeshi Mori, Kayo Ozaki, Yoshiyuki Kosaka
Summary: This study examined the association between conditioning intensity and height growth in pediatric patients who underwent allo-HSCT. The results showed significant differences in height SDS between MAC and RIC groups at 2 and 3 years after allo-HSCT. Multivariate logistic regression analysis indicated that MAC regimen was associated with an increased risk of short stature at 3 years after allo-HSCT.
Review
Immunology
Asim Saha, Bruce R. Blazar
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment option for hematological malignancies. However, conventional allo-HSCT methods have adverse effects and can lead to graft-versus-host-disease. Recent developments in targeted radiotherapy and antibody-based conditioning show promise in improving the outcomes of allo-HSCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Health Care Sciences & Services
Heather R. Wolfe, Mitchell E. Horwitz, Lindsay A. M. Rein
Summary: Primary myelofibrosis is a BCR-ABL1 negative myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells. Allogenic hematopoietic stem cell transplantation may provide a safe and effective curative option for a broader range of primary myelofibrosis patients in the future.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Medicine, Research & Experimental
Erika S. Varady, L. Angel Ayala, Pauline U. Nguyen, Vanessa M. Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A. Greilach, Craig M. Walsh, Matthew A. Inlay
Summary: Donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation increases HSC engraftment and reduces the severity and incidence of graft-versus-host disease (GvHD) in allogeneic hosts.
EMBO MOLECULAR MEDICINE
(2023)
Article
Oncology
Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil, Hildegard Greinix, Thomas Heinicke, Wolfgang Bethge, Dietrich Beelen, Christoph Schmid, Hans Martin, Luca Castagna, Christof Scheid, Kerstin Schaefer-Eckart, Joerg Bittenbring, Juergen Finke, Henrik Sengeloev, Mael Heiblig, Jan Cornelissen, Patrice Chevallier, Mohamad Mohty, Stephen Robinson, Silvia Montoto, Peter Dreger
Summary: This retrospective study analyzed the outcomes of 162 adult patients with BPDCN who underwent a first HCT. The study found that MAC (especially TBI-based) significantly improved the prognosis of alloHCT recipients, and autoHCT could be considered for patients who are not eligible for MAC.
Article
Biophysics
Alexandros Spyridonidis, Myriam Labopin, Tobias Gedde-Dahl, Arnold Ganser, Matthias Stelljes, Charles Craddock, Eva Maria Wagner-Drouet, Jurjen Versluis, Thomas Schroeder, Igor Wolfgang Blau, Gerald. G. Wulf, Peter Dreger, Gitte Olesen, Henrik Sengeloev, Nicolaus Kroger, Victoria Potter, Edouard Forcade, Jakob Passweg, Regis Peffault de Latour, Johan Maertens, Keith M. O. Wilson, Jean Henri Bourhis, Juergen Finke, Eolia Brissot, Ali Bazarbachi, Sebastian Giebel, Bipin P. Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: This study confirms the effectiveness of the recently developed transplant conditioning intensity (TCI) score in predicting mortality and relapse rates in hematopoietic cell transplantation.
BONE MARROW TRANSPLANTATION
(2023)
Article
Pediatrics
Yuhua Qu, Hao Liu, Likun Wei, Shushan Nie, Wenjiao Ding, Sha Liu, Haiyan Liu, Hua Jiang
Summary: This study examined the efficacy of hematopoietic stem cell transplantation (HSCT) for mucopolysaccharidosis (MPS) IV and VI. The results showed that HSCT can restore lysosomal enzyme levels, improve organ function, and increase overall survival rate. Umbilical cord blood (UCB) is a suitable donor source, and using a specific conditioning regimen can achieve better treatment outcomes.
FRONTIERS IN PEDIATRICS
(2022)
Article
Biophysics
Marjan Cruijsen, Jacobien R. Hilberink, Walter J. F. M. van der Velden, Joop H. Jansen, Brigitte Bar, Nicolaas P. M. Schaap, Anton de Haan, Andre B. Mulder, Marco R. de Groot, Frederic Baron, Edo Vellenga, Nicole N. M. Blijlevens, Gerwin Huls
Summary: The combination of decitabine with a standard non-myeloablative conditioning regimen prior to allogeneic hematopoietic cell transplantation can effectively reduce relapse incidence in poor risk AML patients. The study demonstrated a one-year relapse rate of 23% and a one-year overall survival of 70% in this patient population.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Saskia R. Veldkamp, Marc H. A. Jansen, Joost F. Swart, Caroline A. Lindemans
Summary: This case presents a 9-year-old girl with relapsing polychondritis who underwent autoHSCT initially, experienced a relapse, and ultimately achieved long-term disease remission after successful alloHSCT. The case sheds light on the pathogenesis of relapsing polychondritis with a possible role for CD8(+) T cells, and highlights the potential use of alloHSCT as a treatment option for children with severe autoimmune diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Endocrinology & Metabolism
Chantal A. Lebbink, Dorine Bresters, Joni P. B. Tersteeg, Cor van den Bos, Miranda P. Dierselhuis, Eef G. W. M. Lentjes, Annemarie A. Verrijn Stuart, Marta Fiocco, Wim J. E. Tissing, Hanneke M. van Santen
Summary: This prospective study evaluated thyroid function parameters before and 3 months after hematopoietic stem cell transplantation (HSCT) in children. The results showed that the incidence of abnormal thyroid function after 3 months of HSCT was 10%, which was lower than before HSCT (16%). Therefore, thyroid function monitoring may start later after transplantation.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Huina Su, Xinyu Zhou, Yanli Zhao, Yue Lu, DeYan Liu, Janping Zhang, Xin Yang
Summary: This study found that HCT treatment may result in female patients developing POI, which is associated with age, conditioning regimen, and type of blood disease.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Cas S. Dejonckheere, Alexander M. C. Boehner, Eva Schmitz, Tobias A. W. Holderried, Leonard C. Schmeel, Peter Brossart, Frank A. Giordano, Mumtaz A. Koeksal
Summary: A retrospective analysis of 48 adult patients showed that a longer interval of >= 3 days between TBI completion and allo-HSCT was associated with improved overall survival and better peripheral blood kinetics after successful engraftment, suggesting the importance of timing in improving patient outcomes.
Article
Allergy
Rebecca A. Marsh, Kyle Hebert, Soyoung Kim, Christopher C. Dvorak, Victor M. Aquino, K. Scott Baker, Deepak Chellapandian, Blachy Davila Saldana, Christine N. Duncan, Michael J. Eckrich, George E. Georges, Timothy S. Olson, Michael A. Pulsipher, Shalini Shenoy, Elizabeth Stenger, Mark Vander Lugt, Lolie C. Yu, Andrew R. Gennery, Mary Eapen
Summary: Allogeneic hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis (HLH) disorders is associated with substantial morbidity and mortality. The study found that conditioning regimens using flu/melphalan and flu/melphalan/thiotepa had better outcomes compared to other regimens in terms of post-transplant complications and survival rates in HLH patients.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Review
Oncology
Samuel C. F. Couto, Ariel Kowes, Camila S. Aurabi, Theo G. M. Oliveira, Paulo Klinger, Vanderson Rocha
Summary: Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin's lymphoma that affects mature T cells. Recent advancements in treatment options, such as targeted therapies, have shown promise in improving outcomes for patients with PTCL.
FRONTIERS IN ONCOLOGY
(2023)
Letter
Hematology
Smith Giri, Susan Bal, Kelly N. Godby, Gayathri Ravi, Deanna Clark, Clare Ubersax, Abigail Cooley, Priscila White, Sunil Rangarajan, Grant R. Williams, Luciano J. Costa
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
G. Gutierrez-Garcia, C. Martinez, A. Boumendil, H. Finel, R. Malladi, B. Afanasyev, A. Tsoulkani, K. M. O. Wilson, A. Bloor, M. Nikoloudis, D. Richardson, L. Lopez-Corral, L. Castagna, J. Cornelissen, A. Giltat, M. Collin, R. Fanin, F. Bonifazi, S. Robinson, S. Montoto, K. S. Peggs, A. Sureda
Summary: The study found that in high-risk HL patients, a MAC strategy with TCD may be the best option, showing better survival outcomes compared to reduced-intensity conditioning regimens with TCD.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Hematology
Gayathri Ravi, Luciano J. Costa
Summary: Bispecific T cell engagers (TCE) are a promising therapy for multiple myeloma, as they activate T cells and induce lysis of tumor cells by binding to specific proteins on their surfaces. Current development focuses on targeting different proteins and improving their structure and administration. TCEs have shown positive responses in phase 1 trials, with potential toxicities being cytokine release syndrome and cytopenias.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Anna Waszczuk-Gajda, Olaf Penack, Giulia Sbianchi, Linda Koster, Didier Blaise, Peter Remenyi, Nigel Russell, Per Ljungman, Marek Trneny, Jiri Mayer, Simona Iacobelli, Guido Kobbe, Christof Scheid, Jane Apperley, Cyrille Touzeau, Stig Lenhoff, Esa Jantunen, Achilles Anagnostopoulos, Laura Paris, Paul Browne, Catherine Thieblemont, Nicolaas Schaap, Jorge Sierra, Ibrahim Yakoub-Agha, Laurent Garderet, Jan Styczynski, Helene Schoemans, Ivan Moiseev, Rafael F. Duarte, Zinaida Peric, Silvia Montoto, Anja van Biezen, Malgorzata Mikulska, Mahmoud Aljurf, Tapani Ruutu, Nicolaus Kroeger, Curly Morris, Christian Koenecke, Stefan Schoenland, Grzegorz W. Basak
Summary: This post hoc analysis evaluated the rate of infectious and non-infectious complications after ASCT in multiple myeloma patients. The analysis included 3552 patients and found that complication rates decreased over time. Bacterial infections and gastrointestinal complications were the most common early events. The occurrence of complications was not associated with overall survival.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Hematology
Deepak Kumar, Thinh H. Nguyen, Carolyn M. Bennett, Chengyu Prince, Laura Lucas, Sunita Park, Taylor Lawrence, Karin Chappelle, Mariam Ishaq, Edmund K. Waller, Sampath Prahalad, Michael Briones, Shanmuganathan Chandrakasan
Summary: mTOR inhibitors like sirolimus are increasingly used to manage multilineage immune cytopenia (m-IC) in children. However, it is unclear how sirolimus affects the broader immune dysregulation associated with m-IC.
Review
Cell & Tissue Engineering
Muna Qayed, Joseph P. McGuirk, G. Doug Myers, Vinod Parameswaran, Edmund K. Waller, Peter Holman, Margarida Rodrigues, Lee F. Clough, Jennifer Willert
Summary: Chimeric antigen receptor (CAR) T-cell therapy is an individualized immunotherapy that targets and eliminates cancer cells by genetically reprogramming a patient's T cells. The manufacturing process for CART cells is complex, and optimal leukapheresis product is crucial for the success of CAR T-cell therapy.
Article
Peripheral Vascular Disease
Kasra Moazzami, Anurag Mehta, An Young, Devinder Singh Dhindsa, Greg Martin, Ali Mokhtari, Iraj Ghaini Hesaroieh, Amit Shah, J. Douglas Bremner, Viola Vaccarino, Edmund K. Waller, Arshed A. Quyyumi
Summary: This study investigates the relationship between vascular function, circulating progenitor cell (CPC) counts, aging, and exposure to risk factors. The findings suggest that a higher CPC count is associated with better vascular function among younger individuals with risk factors, while this association is not observed in older individuals. Additionally, a lower CPC count is an independent predictor of worsening vascular function.
Article
Hematology
Ulrich Jaeger, Nina Worel, Joseph P. McGuirk, Peter A. Riedell, Isabelle Fleury, Yan Du, Xia Han, David Pearson, Santiago Redondo, Edmund K. Waller
Summary: In the PORTIA trial, it was feasible to add pembrolizumab to tisagenlecleucel for adult patients with r/r DLBCL who had& GE;2 prior lines of therapy and had an Eastern Cooperative Oncology Group performance status of& LE;1. The combination showed a manageable safety profile and had potential efficacy benefits when pembrolizumab was given the day before tisagenlecleucel.
Letter
Hematology
Binod Dhakal, Mei-Jei Zhang, Linda J. Burns, Xiaoying Tang, Christa Meyer, Lih-Wen Mau, Ajay K. Nooka, Edward Stadtmauer, Ivana N. Micallef, Joseph McGuirk, Luciano Costa, Mark B. Juckett, Nina Shah, Richard E. Champlin, Saad Z. Usmani, Sherif S. Farag, Taiga Nishihori, Vivek Roy, Andrew Bodiford, Yvonne J. Barnes, Edward J. Drea, Parameswaran Hari, Mehdi Hamadan
Article
Oncology
David Bernard Miklos, Mohammad Abu Zaid, Julian P. Cooney, Joern C. Albring, Mary Flowers, Alan P. Skarbnik, Ibrahim Yakoub-Agha, Bor-Sheng Ko, Benedetto Bruno, Edmund K. Waller, Jean Yared, Sang Kyun Sohn, Claude-Eric Bulabois, Takanori Teshima, David Jacobsohn, Hildegard Greinix, Ahmad Mokatrin, Yihua Lee, Justin T. Wahlstrom, Lori Styles, Gerard Socie
Summary: In this study, the safety and efficacy of ibrutinib with prednisone in patients with chronic graft-versus-host disease were evaluated. The primary and secondary end points did not show a statistically significant difference between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Ajai Chari, Monique C. Minnema, Jesus G. Berdeja, Albert Oriol, Niels W. C. J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Raluca Verona, Suzette Girgis, Shiyi Yang, Rachel B. Goldsmith, Xiang Yao, Kodandaram Pillarisetti, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Amrita Krishnan
Summary: Talquetamab treatment exhibited common adverse events like cytokine release syndrome, skin-related events, and dysgeusia, which were primarily low-grade; however, the drug induced substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Hematology
Ariel Kleman, Arun Singavi, Lauren Pommert, Angela J. Mathison, Parameswaran Hari, Binod Dhakal, Meera Mohan, Siegfried Janz, Jennifer M. Knight, Mithun Shah, Carolina Schinke, Robert Burns, George Francis Steinhardt, Sridhar Rao, Karen Carlson
Article
Hematology
Saurabh Chhabra, Natalie Callander, Nicole L. Watts, Luciano J. Costa, Bicky Thapa, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Larry D. Anderson, Susan Bal, Binod Dhakal, Nitya Nathwani, Nina Shah, Eva Medvedova, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Timothy Schmidt, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, R. Frank Cornell, James H. Jerkins, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees
Summary: For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care includes induction therapy followed by autologous stem cell transplantation (ASCT). Daratumumab as monotherapy and in combination treatment is approved across multiple lines of therapy for multiple myeloma (MM), and lenalidomide is an effective and commonly used agent for induction and maintenance therapy in MM. However, there is concern that lenalidomide and daratumumab given as induction therapy might impair mobilization of stem cells for ASCT.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Meeting Abstract
Oncology
Ishani H. Rao, Rohan Dhamsania, Edmund K. Waller, Sanjay Chandrasekaran